GlassScriptPhysician profile
Elizabeth Benfield
NPI 1700972890
$11,603.45
in general payments reported to CMS, 2019-2025
27 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,299 · 2022: $3,066 · 2023: $2,677 · 2024: $2,444 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,237.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,482.40 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $1,793.30 | 2021-2025 | |
| Ucb, INC. | $1,135.41 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,133.17 | 2021-2025 | |
| Shockwave Medical, INC | $944.84 | 2022 | |
| Janssen Biotech, INC. | $556.99 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $523.62 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $478.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $468.12 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $287.95 | 2021-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.60 | 2021-2024 | Cyltezo |
| Radius Health, INC. | $106.14 | 2021-2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $83.90 | 2023-2025 | Orencia |
| Genzyme Corporation | $73.95 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $69.49 | 2021-2024 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $53.74 | 2024-2025 | Tyenne |
| Sandoz INC. | $34.11 | 2023 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $33.70 | 2021 | |
| Organon LLC | $26.10 | 2025 | Hadlima |
| Abbott Laboratories | $24.85 | 2024 | Eterna |
| Pharmacosmos Therapeutics INC. | $24.25 | 2024 | Monoferric |
| Horizon Therapeutics Plc | $22.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2023 | Hyqvia |
| Novo Nordisk INC | $18.35 | 2023 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $15.36 | 2021 | |
| Boston Scientific Corporation | $13.15 | 2024 | Orcapod |
| Arbor Pharmaceuticals, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Benfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.